EC expands indication for Vertex' Kaftrio

23 November 2023

The European Commission has granted approval for the label expansion of Kaftrio (ivacaftor/tezacaftor/elexacaftor; marketed in the USA as Trikaftra) in a combination regimen with ivacaftor for the treatment of children with cystic fibrosis (CF) ages two through five years old who have at least one F508del mutation in the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) gene, US biopharma Vertex Pharmaceuticals (Nasdaq: VRTX) announced today.

“In addition to data from clinical trials, long-term and real-world data have demonstrated the significant clinical benefit of Kaftrio in eligible people living with CF, and today’s news means that young children across Europe can now benefit from this important medicine,” said Dr Carmen Bozic, executive vice president, global medicines development and medical affairs, and chief medical officer of Vertex.

Kaftrio/Trikaftra received strong international uptake in the third quarter of this year, with net product revenues up 6% to $929 million ex-USA. Sales were up 7% at $1.55 billion in the USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK